Evaluating the impact of early vs delayed ofatumumab initiation and estimating the long-term outcomes of ofatumumab vs teriflunomide in relapsing multiple sclerosis patients in Spain

References

• Fernández O, Fernández V, Guerrero M, et al. Multiple sclerosis prevalence in Malaga, Southern Spain estimated by the capture-recapture method. Mult Scler. 2012;18(3):372–376.
   PubMed Web of Science ®Google Scholar
• Multiple Sclerosis International Federation (MSIF). Atlas of MS. 2013. [cited 2021 Nov 28]. https://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf
   Google Scholar
• Fernández O, Calleja-Hernández MA, Meca-Lallana J, et al. Estimate of the cost of multiple sclerosis in Spain by literature review. Expert Rev Pharmacoecon Outcomes Res. 2017;17(4):321–333.
   PubMed Web of Science ®Google Scholar
• Filippi M, Danesi R, Derfuss T, et al. Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis. J Neurol. 2022;269(3):1670–1677.
   PubMed Web of Science ®Google Scholar
• Iaffaldano P, Lucisano G, Caputo F, et al. Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Ther Adv Neurol Disord. 2021;14:175628642110195.
   Web of Science ®Google Scholar
• Harding K, Williams O, Willis M, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol. 2019;76(5):536–541.
   PubMed Web of Science ®Google Scholar
• He A, Merkel B, Brown JWL, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19(4):307–316.
   PubMed Web of Science ®Google Scholar
• Merkel B, Butzkueven H, Traboulsee AL, et al. Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: a systematic review. Autoimmun Rev. 2017;16(6):658–665.
   PubMed Web of Science ®Google Scholar
• Simonsen CS, Flemmen HØ, Broch L, et al. Early high efficacy treatment in multiple sclerosis is the best predictor of future disease activity over 1 and 2 years in a Norwegian population-based registry. Front Neurol. 2021;12:693017.
   PubMed Web of Science ®Google Scholar
• Scolding N, Barnes D, Cader S, et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol. 2015;15(4):273–279.
   PubMedGoogle Scholar
• Marques VD, Passos GRD, Mendes MF, et al. Brazilian consensus for the treatment of multiple sclerosis: Brazilian Academy of Neurology and Brazilian Committee on treatment and research in multiple sclerosis. Arq Neuropsiquiatr. 2018;76(8):539–554.
   PubMed Web of Science ®Google Scholar
• Grand’Maison F, Yeung M, Morrow SA, et al. Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis, perspectives and approaches. Neural Regen Res. 2018;13(11):1871–1874.
   PubMed Web of Science ®Google Scholar
• Inshasi JS, Almadani A, Fahad SA, et al. High-efficacy therapies for relapsing-remitting multiple sclerosis: implications for adherence. An expert opinion from the United Arab Emirates. Neurodegener Dis Manag. 2020;10(4):257–266.
   PubMed Web of Science ®Google Scholar
• Samjoo IA, Worthington E, Drudge C, et al. Efficacy classification of modern therapies in multiple sclerosis. J Comp Eff Res. 2021;10(6):495–507.
   PubMed Web of Science ®Google Scholar
• Margoni M, Preziosa P, Filippi M, et al. Anti-CD20 therapies for multiple sclerosis: current status and future perspectives. J Neurol. 2022;269(3):1316–1334.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Ofatumumab (Kesimpta). [cited 2021 Sep 15]. https://www.ema.europa.eu/en/documents/overview/kesimpta-epar-medicine-overview_en.pdf
   Google Scholar
• Gartner J, Hauser S, Bar‐Or A, et al. Benefit-risk of ofatumumab in treatment-naïve early relapsing multiple sclerosis patients. Mult Scler J. 2020;26(3 suppl):210.
   PubMedGoogle Scholar
• Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383(6):546–557.
   PubMed Web of Science ®Google Scholar
• Buron MD, Chalmer TA, Sellebjerg F, et al. Initial high-efficacy disease-modifying therapy in multiple sclerosis: a nationwide cohort study. Neurology. 2020;95(8):e1041–e1051.
   PubMed Web of Science ®Google Scholar
• Kavaliunas A, Manouchehrinia A, Stawiarz L, et al. Importance of early treatment initiation in the clinical course of multiple sclerosis. Mult Scler. 2017;23(9):1233–1240.
   PubMed Web of Science ®Google Scholar
• Prosperini L, Mancinelli CR, Solaro CM, et al. Induction versus escalation in multiple sclerosis: a 10-year real world study. Neurotherapeutics. 2020;17(3):994–1004.
   PubMed Web of Science ®Google Scholar
• Spelman T, Magyari M, Piehl F, et al. Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies. JAMA Neurol. 2021;78(10):1197–1204.
   PubMed Web of Science ®Google Scholar
• Mauskopf JA, Paul JE, Grant DM, et al. The role of cost-consequence analysis in healthcare decision-making. Pharmacoeconomics. 1998;13(3):277–288.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Teriflunomide (Aubagio) summary of product characteristics. [cited 2021 Sep 15]. https://www.ema.europa.eu/en/documents/product-information/aubagio-epar-product-information_en.pdf
   Google Scholar
• Taheri S, Sahraian MA, Yousefi N. Cost-effectiveness of alemtuzumab and natalizumab for relapsing-remitting multiple sclerosis treatment in Iran: decision analysis based on an indirect comparison. J Med Econ. 2019;22(1):71–84.
   PubMed Web of Science ®Google Scholar
• Baharnoori M, Bhan V, Clift F, et al. Cost-effectiveness analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada. Pharmacoecon Open. 2022;6(6):859–870.
   PubMed Web of Science ®Google Scholar
• Versteegh MM, Huygens SA, Wokke BWH, et al. Effectiveness and cost-effectiveness of 360 disease-modifying treatment escalation sequences in multiple sclerosis. Value Health. 2022;25(6):984–991.
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs & Technologies in Health (CADTH). CADTH common drug review. Pharmacoeconomic review report Ocrelizumab (Ocrevus) version 1.0. 2017. [cited 2022 Oct 31]. Available from: https://www.cadth.ca/sites/default/files/cdr/pharmacoeconomic/SR0519_Ocrevus_RMS%20_PE_Report.pdf
   Google Scholar
• Palace J, Bregenzer T, Tremlett H, et al. UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved markov model. BMJ Open. 2014;4(1):e004073.
   PubMed Web of Science ®Google Scholar
• Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain. 2010;133(Pt 7):1914–1929.
   PubMed Web of Science ®Google Scholar
• Orme M, Kerrigan J, Tyas D, et al. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health. 2007;10(1):54–60.
   PubMed Web of Science ®Google Scholar
• Patzold U, Pocklington PR. Course of multiple sclerosis. First results of a prospective study carried out of 102 MS patients from 1976–1980. Acta Neurol Scand. 1982;65(4):248–266.
   PubMed Web of Science ®Google Scholar
• Samjoo IA, Worthington E, Drudge C, et al. Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis. J Comp Eff Res. 2020;9(18):1255–1274.
   PubMed Web of Science ®Google Scholar
• Office for National Statistics reference. Spain life expectancy. [cited 2021 Sep 20]. Available from: https://www.ine.es/en/index.htm
   Google Scholar
• Pokorski RJ. Long-term survival experience of patients with multiple sclerosis. J Insur Med. 1997;29(2):101–106.
   PubMedGoogle Scholar
• Cho JY, Hong KS, Kim HJ, et al. Disability weight for each level of the Expanded Disability Status Scale in multiple sclerosis. Mult Scler. 2014;20(9):1217–1223.
   PubMed Web of Science ®Google Scholar
• Oreja-Guevara C, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: results for Spain. Mult Scler. 2017;23(2_suppl):166–178.
   PubMed Web of Science ®Google Scholar
• Thompson A, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: results for the United Kingdom. Mult Scler. 2017;23(2_suppl):204–216.
   PubMed Web of Science ®Google Scholar
• Gisbert R, Brosa M. Spanish health costs and cost-effectiveness ratios database: ESALUD [Online]. [cited 2021 Sep 20]. Available from: http://esalud.oblikue.com/
   Google Scholar
• Hawton AJ, Green C. Multiple sclerosis: relapses, resource use, and costs. Eur J Health Econ. 2016;17(7):875–884.
   PubMed Web of Science ®Google Scholar
• The Organisation for Economic Co-operation and Development. [cited 2021 Sep 20]. Available from: https://www.oecd.org/spain/
   Google Scholar
• Simpson A, Mowry EM, Newsome SD. Early aggressive treatment approaches for multiple sclerosis. Curr Treat Options Neurol. 2021;23(7):19.
   PubMed Web of Science ®Google Scholar
• García Merino A, Ara Callizo JR, Fernández Fernández O, et al. Consensus statement on the treatment of multiple sclerosis by the Spanish Society of Neurology in 2016. Neurologia. 2017;32(2):113–119.
   PubMed Web of Science ®Google Scholar
• Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24(2):96–120.
   PubMed Web of Science ®Google Scholar
• Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology. 2018;90(17):777–788.
   PubMed Web of Science ®Google Scholar
• Wiendl H, Gold R, Zipp F. Multiple sclerosis therapy consensus group (MSTCG): answers to the discussion questions. Neurol Res Pract. 2021;3(1):44.
   PubMedGoogle Scholar
• Bosco-Lévy P, Debouverie M, Brochet B, et al. Comparative effectiveness of dimethyl fumarate in multiple sclerosis. Br J Clin Pharmacol. 2022;88(3):1268–1278.
   PubMed Web of Science ®Google Scholar
• Chen J, Taylor BV, Blizzard L, et al. Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data. J Neurol Neurosurg Psychiatry. 2018;89(11):1200–1207.
   PubMed Web of Science ®Google Scholar
• Lee A, Pike J, Edwards MR, et al. Quantifying the benefits of dimethyl fumarate over β interferon and glatiramer acetate therapies on work productivity outcomes in MS patients. Neurol Ther. 2017;6(1):79–90.
   PubMed Web of Science ®Google Scholar
• Neuberger EE, Abbass IM, Jones E, et al. Work productivity outcomes associated with ocrelizumab compared with other disease-modifying therapies for multiple sclerosis. Neurol Ther. 2021;10(1):183–196.
   PubMed Web of Science ®Google Scholar